Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최충혁 | - |
dc.date.accessioned | 2019-11-25T01:42:22Z | - |
dc.date.available | 2019-11-25T01:42:22Z | - |
dc.date.issued | 2017-05 | - |
dc.identifier.citation | BMC MUSCULOSKELETAL DISORDERS, v. 18, Article no. 223 | en_US |
dc.identifier.issn | 1471-2474 | - |
dc.identifier.uri | https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-017-1591-4 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/113956 | - |
dc.description.abstract | Background: This randomized, double-blind, multi-center, non-inferiority trial was conducted to assess the efficacy and safety of a cross-linked hyaluronate (XLHA, single injection form) compared with a linear high molecular hyaluronate (HMWHA, thrice injection form) in patients with symptomatic knee osteoarthritis.Methods: Two hundred eighty seven patients with osteoarthritis (Kellgren-Lawrence grade I to III) were randomized to each group. Three weekly injections were given in both groups but two times of saline injections preceded XLHA injection to maintain double-blindness. Primary endpoint was the change of weight-bearing pain (WBP) at 12 weeks after the last injection. Secondary endpoints included Western Ontario and McMaster Universities Osteoarthritis index; patient's and investigator's global assessment; pain at rest, at night, or in motion; OMERACT-OARSI responder rate; proportion of patients achieving at least 20 mm or 40% decrease in WBP; and rate of rescue medicine use and its total consumption.Results: Mean changes of WBP at 12 weeks after the last injection were -33.3 mm with XLHA and -29.2 mm with HMWHA, proving non-inferiority of XLHA to HMWHA as the lower bound of 95% CI (-1.9 mm, 10.1 mm) was well above the predefined margin (-10 mm). There were no significant between-group differences in all secondary endpoints. Injection site pain was the most common adverse event and no remarkable safety issue was identified.Conclusions: This study demonstrated that a single injection of XLHA was non-inferior to three weekly injections of HMWHA in terms of WBP reduction, and supports XLHA as an effective and safe treatment for knee osteoarthritis. | en_US |
dc.description.sponsorship | This study was funded by LG Life Sciences, Ltd. The funding sources had no involvement in the study design, collection, analysis, interpretation of the data, writing of the manuscript, or in the decision to submit the manuscript for publication. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | BMC | en_US |
dc.subject | Knee osteoarthritis | en_US |
dc.subject | Inflammation | en_US |
dc.subject | Treatment | en_US |
dc.subject | Hyaluronic acid | en_US |
dc.title | Efficacy and safety of single injection of cross-linked sodium hyaluronate vs. three injections of high molecular weight sodium hyaluronate for osteoarthritis of the knee: a double-blind, randomized, multi-center, non-inferiority study | en_US |
dc.type | Article | en_US |
dc.relation.volume | 18 | - |
dc.identifier.doi | 10.1186/s12891-017-1591-4 | - |
dc.relation.page | 223-232 | - |
dc.relation.journal | BMC MUSCULOSKELETAL DISORDERS | - |
dc.contributor.googleauthor | Ha, Chul-Won | - |
dc.contributor.googleauthor | Park, Yong-Beom | - |
dc.contributor.googleauthor | Choi, Chong-Hyuk | - |
dc.contributor.googleauthor | Kyung, Hee-Soo | - |
dc.contributor.googleauthor | Lee, Ju-Hong | - |
dc.contributor.googleauthor | Yoo, Jae Doo | - |
dc.contributor.googleauthor | Yoo, Ju-Hyung | - |
dc.contributor.googleauthor | Choi, Choong-Hyeok | - |
dc.contributor.googleauthor | Kim, Chang-Wan | - |
dc.contributor.googleauthor | Kim, Hee-Chun | - |
dc.relation.code | 2017004443 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | chhchoi | - |
dc.identifier.orcid | http://orcid.org/0000-0002-9080-4904 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.